Cns Drugs

SCI SCIE

国际简称：CNS DRUGS 参考译名：中枢神经系统药物

主要研究方向：医学-精神病学非预警期刊审稿周期：较慢,6-12周

《中枢神经系统药物》(Cns Drugs)是一本由Springer International Publishing出版的以医学-精神病学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

1区中科院分区
Q1 JCR分区
94 年发文量
7 IF影响因子
未开放 是否OA
100 H-index
1994 创刊年份
Monthly 出版周期
English 出版语言

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes:

- Overviews of contentious or emerging issues.

- Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses.

- Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

- Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry.

- Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

[ 查看全部 ]

投稿咨询加急咨询

Cns Drugs期刊信息

ISSN：1172-7047
出版语言：English
是否OA：未开放
E-ISSN：1179-1934
出版地区：NEW ZEALAND
是否预警：否
出版商：Springer International Publishing
出版周期：Monthly
创刊时间：1994
开源占比：0.4419
Gold OA文章占比：55.83%
OA被引用占比：0.2897...
出版国人文章占比：0.03
出版撤稿占比：0
研究类文章占比：51.06%

Cns Drugs CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

13.7

2.161

2.42

学科类别	分区	排名	百分位
大类：Medicine 小类：Psychiatry and Mental Health	Q1	20 / 580	96%
大类：Medicine 小类：Neurology (clinical)	Q1	15 / 403	96%
大类：Medicine 小类：Pharmacology (medical)	Q1	11 / 278	96%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Cns Drugs中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CLINICAL NEUROLOGY 临床神经病学 PHARMACOLOGY & PHARMACY 药学 PSYCHIATRY 精神病学	1区 1区 1区

Cns Drugs JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：CLINICAL NEUROLOGY	SCIE	Q1	24 / 296	92.1
学科：PHARMACOLOGY & PHARMACY	SCIE	Q1	33 / 356	90.9
学科：PSYCHIATRY	SCIE	Q1	22 / 293	92.7
学科：CLINICAL NEUROLOGY	SCIE	Q1	26 / 296	91.39
学科：PHARMACOLOGY & PHARMACY	SCIE	Q1	22 / 356	93.96
学科：PSYCHIATRY	SCIE	Q1	21 / 293	93

Cns Drugs历年数据统计

影响因子

中科院分区

Cns Drugs中国学者发文选摘

1、Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Strok
Author: Pu, Lanlan; Liu, Jiahui; Kong, Shuying; Joyama, Yuki; Gong, Xing; Ji, Xiaofei; Dong, Huijie

Journal: CNS DRUGS. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40263-026-01278-9
2、Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Strok
Author: Wang, Jing; Li, Sijie; Ma, Qingfeng; Ji, Xunming; Wu, Longfei; Zhao, Wenbo

Journal: CNS DRUGS. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40263-026-01271-2
3、Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review (vol 38, pg 807, 2024
Author: Bosch, Anemoon T.; Sander, Josemir W.; Thijs, Roland D

Journal: CNS DRUGS. 2025; Vol. 39, Issue 5, pp. 525-525. DOI: 10.1007/s40263-025-01176-6
4、Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment Target
Author: Almulla, Abbas F.; Maes, Michael

Journal: CNS DRUGS. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40263-025-01195-3
5、Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studie
Author: Li, Qian; Li, Yang; Yang, Yishen; Zhuo, Jianmin; Jia, Miaomiao; Ye, Chong; Si, Tianmei

Journal: CNS DRUGS. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40263-025-01194-4
6、Efficacy and Safety of Escitalopram Combined with Tandospirone Citrate in Treating Patients with Vascular Depression and Chronic Insomnia: A Randomized Controlled Tria
Author: Chen, Hongbin; Zeng, Guiying; Wu, Shufang; Xie, Sengpei; Chen, Xinyan; Wu, Weiwei; Chen, Hui; Chen, Ronghua; Xiao, Yingchun

Journal: CNS DRUGS. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40263-025-01190-8
7、Comment on A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
Author: Wang, Chenxi; Tian, Huichuan; Shang, Jin

Journal: CNS DRUGS. 2025; Vol. 39, Issue 2, pp. 209-210. DOI: 10.1007/s40263-024-01152-6
8、Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Tria
Author: Tian, Wen; Cao, Hua; Li, Xidan; Gong, Xing; Yu, Xinting; Li, Dongyun; Xie, Jing; Bai, Ying; Zhang, Dawei; Li, Xiaohong; Xu, Ping; Liu, Jiahui; Zhang, Bingwei; Ji, Xiaofei; Dong, Huijie

Journal: CNS DRUGS. 2025; Vol. 39, Issue 2, pp. 197-208. DOI: 10.1007/s40263-024-01145-5